Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03

被引：0
作者：
Saura, Cristina
Cortes, Javier
Modi, Shanu
Kim, Sung-Bae
Hamilton, Erika P.
Hurvitz, Sara A.
Krop, Ian E.
Curigliano, Giuseppe
Iwata, Hiroji
Im, Seock-Ah
Herbolsheimer, Pia Maarit
Karnoub, Maha
Gambhire, Dhiraj
Egorov, Anton
Andre, Fabrice
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Quironsalud Grp, Int Breast Canc Ctr IBCC, Pangaea Oncol, Barcelona, Spain
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Univ Washington, Sch Med, Seattle, WA USA
[7] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[8] Yale Canc Ctr, New Haven, CT USA
[9] Univ Milan, Milan, Italy
[10] IRCCS, European Inst Oncol, Milan, Italy
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst,Natl Univ Hosp, Seoul, South Korea
[13] AstraZeneca, Gaithersburg, MD USA
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Daiichi Sankyo, Basking Ridge, NJ USA
[16] Univ Paris Saclay, Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1023
引用
收藏
页数：1
相关论文
共 50 条
[41]   Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia [J].
Wolf, M. ;
Sili, F. ;
Sulejmani, V. ;
Schuepferling, A. ;
Bomhard, J. ;
Huber, M. ;
Sigl, S. ;
Schnelzer, A. .
GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) :E44-E44
[42]   Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) [J].
Tsurutani, J. ;
Jacot, W. ;
Yamashita, T. ;
Riaz, F. ;
Yerushalmi, R. ;
Im, S-A. ;
Niikura, N. ;
Halser-Strub, U. ;
Cortes, J. ;
Wennstig, A-K. ;
Chae, Y. ;
Wang, X. ;
Li, W. ;
Simon, H. ;
Masci, G. ;
Tamburini, E. ;
Aguilar, C. Orbegoso ;
Tecson, K. ;
Yung, L. ;
Modi, S. .
ANNALS OF ONCOLOGY, 2023, 34 :S342-S343
[43]   Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis [J].
Jerusalem, Guy ;
Park, Yeon Hee ;
Yamashita, Toshinari ;
Hurvitz, Sara A. ;
Modi, Shanu ;
Andre, Fabrice ;
Krop, Ian E. ;
Farre, Xavier Gonzalez ;
You, Benoit ;
Saura, Cristina ;
Kim, Sung-Bae ;
Osborne, Cynthia R. ;
Murthy, Rashmi K. ;
Gianni, Lorenzo ;
Takano, Toshimi ;
Liu, Yali ;
Cathcart, Jillian ;
Lee, Caleb ;
Perrin, Christophe .
CANCER DISCOVERY, 2022, 12 (12) :2754-2762
[44]   Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC) [J].
Ueno, N. T. ;
Jacot, W. ;
Yamashita, T. ;
Sohn, J. ;
Tokunaga, E. ;
Prat, A. ;
Tsurutani, J. ;
Park, Y. H. ;
Rugo, H. S. ;
Xu, B. ;
Cardoso, F. ;
Mitri, Z. ;
Mahtani, R. ;
Dunton, K. ;
Wang, Y. ;
Gambhire, D. ;
Cottone, F. ;
Harbeck, N. ;
Cameron, D. A. ;
Modi, S. .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S632-S633
[45]   Exposureefficacy and safety analysis of trastuzumab deruxtecan (T-DXd) in patients with advanced/metastatic HER2+breast cancer (BC): Analyses from Phase 3 Studies DESTINYBreast02 (DB-02) and DESTINYBreast03 (DB-03) [J].
Li, Claire ;
Wada, Russ ;
Li, Hanbin ;
Kastrissios, Helen ;
Abutarif, Malaz ;
Garimella, Tushar ;
Khatri, Amit .
CANCER RESEARCH, 2024, 84 (09)
[46]   Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 [J].
Modi, Shanu ;
Niikura, Naoki ;
Yamashita, Toshinari ;
Jacot, William ;
Sohn, Joohyuk ;
Tokunaga, Eriko ;
Vidal, Maria Jesus ;
Park, Yeon Hee ;
Lee, Keun Seok ;
Chae, Yeesoo ;
Ueno, Naoto T. ;
Prat, Aleix ;
Suto, Fumitaka ;
Kuwahara, Yusuke ;
McEwen, Robert ;
Feng, Wenqin ;
Goto, Hiroki ;
Orbegoso, Cecilia ;
Cameron, David A. ;
Tsurutani, Junji .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47]   Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02) [J].
Siena, Salvatore ;
Raghav, Kanwal ;
Takashima, Atsuo ;
Kato, Takeshi ;
Van den Eynde, Marc ;
Pietrantonio, Filippo ;
Komatsu, Yoshito ;
Kawakami, Hisato ;
Peeters, Marc ;
Andre, Thierry ;
Lonardi, Sara ;
Yamaguchi, Kensei ;
Tie, Jeanne ;
Castro, Cristina Gravalos ;
Strickler, John H. ;
Shiose, Yoshinobu ;
Koga, Makito ;
Boran, Aislyn ;
Haribhai, Dipica ;
Goto, Hiroki ;
Barrios, Daniel ;
Abe, Kodai ;
Yoshino, Takayuki .
CANCER RESEARCH, 2025, 85 (08)
[48]   Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab [J].
Olson, E. M. ;
Najita, J. S. ;
Sohl, J. ;
Arnaout, A. ;
Winer, E. P. ;
Lin, N. U. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[49]   A meta-analysis analyzing the efficacy of trastuzumab-deruxtecan (T-DXd) on central nervous system (CNS) disease in patients with metastatic breast cancer (mBC) [J].
Kumar, Prashanth Ashok ;
Sandhu, Michael ;
Sravanthi, Metlapalli Venkata ;
Desai, Devashish ;
Kumar, Vishnu Charan Suresh ;
Benjamin, Sam .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50]   TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC) [J].
Lin, N. U. ;
Mayer, I. A. ;
Hobday, T. J. ;
Falkson, C. I. ;
Dees, E. C. ;
Nanda, R. ;
Krop, I. E. ;
Rimawi, M. F. ;
Wolff, A. C. ;
Winer, E. P. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345